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Abstract. Genomic abnormalities are the hallmark of cancers 
and may harbor potential candidate genes important for cancer 
development and progression. We performed array compara-
tive genomic hybridization (array CGH) on 36 cases of 
primary lung adenocarcinoma (AD) using an array containing 
2621 BAC or PAC clones spanning the genome at an average 
interval of 1 Mb. Array CGH identified the commonest aber-
rations consisting of DNA gains within 1p, 1q, 5p, 5q, 7p, 7q, 
8q, 11q, 12p, 13q, 16p, 17q, 20q, and losses with 6q, 9p, 10q 
and 18q. High-level copy gains involved mainly 7p21-p15 and 
20q13.3. Dual color fluorescence in situ hybridization (FISH) 
was performed on a selective locus for validation of array CGH 
results. Genomic aberrations were compared with different 
clinicopathological features and a trend of higher number of 
aberrations in tumors with aggressive phenotypes and current 
tobacco exposure was identified. According to array CGH data, 
23 candidate genes were selected for quantitative PCR (qPCR) 
analysis. The concordance observed between the genomic and 
expression changes in most of the genes suggested that they 
could be candidate cancer-related genes that contributed to the 
development of lung AD.
Introduction
Lung cancer is the most frequent cause of cancer-related death 
worldwide, according for ~1.4 million deaths per year (1). 
Adenocarcinoma (AD) predominates over squamous, large 
cell or small cell carcinomas as the major tumor type and 
involves different carcinogenic mechanisms besides tobacco 
genotoxicity. The identification of multiple genetic abnormali-
ties which drive oncogenic signaling pathways, such as EGFR 
mutations and ALK fusions, has led to the development of new 
targeted therapies in a subset of patients (2,3). However, the 
molecular mechanism in many AD patients still remains to be 
understood. 
Array comparative genomic hybridization (array CGH) 
facilitates gene discovery by enabling precise mapping of the 
clones of interest to specific locations on the human genome 
map. With increasing density of clone coverage of the genome, 
it has been shown that small DNA aberrations at sub-megabase 
levels can be identified (4). Our previous analyses on lung 
ADs with metaphase CGH have demonstrated several typical 
genomic aberrations. However, aberrations <10-20 Mb could 
be difficult to identify and little is known about the candidate 
tumor genes residing in them.
In the present study, we detected 36 lung AD cases by 
array CGH to identify genomic imbalances, using an array that 
consists of BAC or PAC clones covering the whole genome at 
an average of 1 Mb interval. Then comparison between patient 
groups was also performed to identify aberrations associ-
ated with clinical and tumor characteristics. Furthermore, 
23 selected genes according to array data were studied by 
real-time quantitative PCR (real-time qPCR) to identify the 
potential candidate genes that could play a critical role in AD 
progression.
Materials and methods
Study samples. Resection specimens of 36 ADs were recruited 
for study with written informed consent at the Grantham 
Hospital, Hong Kong after institutional review board approval. 
All patients were ethnic Chinese, and none had received any 
preoperative radiation therapy or chemotherapy. Demographic 
and clinical data were collected by the designated clinician. 
Non-smokers (NS) were patients who had smoked <100 ciga-
rettes in the life-time; ex-smokers (EX) were those who had 
consumed >100 cigarettes but who had stopped smoking for at 
least one year before recruitment; current smokers (SM) were 
patients who were still smoking at the time of recruitment; 
passive smokers (PS) were those regularly exposed to envi-
ronmental tobacco smoke at home or at work places. Tumor 
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classification and grading were independently performed by 2 
qualified pathologists according to the WHO classification of 
lung tumors (2004). Details of the clinicopathological data of 
the 36 patients were shown in Table Ⅰ.
Tumor tissues were snap frozen within 30 min of resection 
and kept at -70˚C until use. Haematoxylin and eosin stained 
sections were examined histologically prior to DNA and 
RNA extraction. Areas showing high tumor cell density with 
preserved morphology, low stromal and inflammatory cell 
content were dissected for study, and non-neoplastic or necrotic 
areas were avoided or dissected away to ensure the presence of 
at least 70% of tumor content. Peripheral blood mononuclear 
cells of 15 each of male or female young healthy adults were 
examined cytogenetically to ensure normal karyotypes, after 
which DNA was extracted, pooled and used as reference DNA 
for array CGH. For real-time qPCR, to ensure comparability 
of results from different test samples, all the cDNA used in the 
present study were prepared from a fixed amount of starting 
RNA and reverse-transcribed according to the same protocol 
after strict quality check to ensure absence of RNA degrada-
tion. All aliquots of samples and replicates of each case used 
in the analysis of every gene were taken from the same sample 
stock to ensure consistency of quality and amount of material 
input.
Array CGH and data analysis. The DNA microarray 
contained 2621 non-overlapping BAC and PAC clones in 
duplicates that spanned the entire genome at an average 
density of 1 Mb per clone (Human BAC Arrays; Spectral 
Genomics, Inc., Houston, TX, USA). Clone information was 
provided by the chip manufacturer and clone position was 
mapped according to the National Center for Biotechnology 
Information MapViewer database, build 37.2. Extracted tumor 
and reference DNA was treated with RNase A and digested 
by DpnII (New England Biolabs), followed by purification 
using high pure PCR product purification kit (Roche). Each of 
test and reference DNA (0.5 µg) were, respectively, labeled by 
BioPrime® DNA Labeling kit (Invitrogen), modified to include 
dATP, dGTP and dTTP (10 nmol each), dCTP (0.3 nmol), 
Cy5-dCTP or Cy3-dCTP (0.3 nmol) and 1 µl Klenow fragment 
in a 50 µl reaction volume. Unincorporated nucleotides were 
removed by MicroSpin G-50 columns (Amersham Pharmacia 
Biotech, Inc., Piscataway, NJ, USA). Probe size was optimized 
to 100-700 bp. Labeled test and sex-matched reference DNA 
were co-precipitated with human Cot-1 DNA and Salmon 
Sperm Testis DNA and resuspended in 50 µl of hybridization 
buffer. For hybridization, the probe mix was first denatured 
and incubated at 37˚C for 60 min to allow pre-annealing of 
Cot-1 DNA. It was then added to the array under a glass cover-
slip and hybridized for 16-18 h at 37˚C. Afterwards, the arrays 
were washed briefly in 2X SSC/0.5% SDS, 50% formamide/2X 
SSC at 50˚C for 20 min, 2X SSC/0.1% NP40 for 20 min and 
finally 0.2X SSC for 10 min at 50˚C. The arrays were then 
rinsed in water and air dried. For each sample, two separate 
hybridizations were performed with reversed dye labeling to 
obtain 2 reciprocal datasets for analysis.
Hybridization signals were scanned with ScanArray 
5000 (Packard BioScience) and captured images were 
analyzed using QuantArray 3.0 software (Packard BioChip 
Technologies). For each array, the Cy5/Cy3 signal intensity 
ratios were normalized according to the recommendations of 
the chip manufacturer. Briefly, the mean ratio and standard 
deviation (SD) of all target spots were calculated. A normal-
ization constant was then derived from spots within the overall 
mean ± 1.5 SD range. Readings from duplicate targets were 
averaged to yield a single intensity ratio. Cy5/Cy3 intensity 
ratios of <0.85 or >1.15 were considered to show DNA copy 
number alterations (CNA). These threshold values were 
similar to those adopted in other array CGH studies of solid 
tumors using BAC array platforms (5,6). High level CNA 
were designated for ratios of <0.5 and >1.5. Two repeats of 
normal vs. normal hybridizations with pooled normal DNA 
were performed to ensure consistency of criteria. For each 
target, the final status of DNA gain or loss was assigned only 
if the reciprocal ratios of the dye-reversal experiments yielded 
concordant results. Loci showing imbalances in the control 
experiments or with inconsistent map positions were omitted 
during data interpretation.   
Fluorescence in situ hybridization (FISH). Dual color FISH 
analysis was performed on paraffin tumor tissue sections. PAC 
clone RP5-885L7 (20q13.3, 60.9 Mb), corresponding to loci 
of DNA gain by array CGH, was used as test probe. The test 
probes were labeled by nick translation with SpectrumOrange 
(Vysis, Downers Grove, IL, USA). Procedures of probe 
labeling and FISH analysis were according to previously 
published protocols (7).
Table Ⅰ. Clinicopathological data of 36 primary lung adeno-
carcinomas.
 No. % of total
Gender
  Female 24 67
  Male 12 33
Age (years)
  <50 3 8
  50-59 11 31
  60-69 12 33
  ≥70 10 28
Smoking history
  Non-smoker 22 61
  Current smoker 8 22
  Ex-smoker 2 6
  Passive smoker 4 11
Differentiation
  Well 18 50
  Moderate 15 42
  Poor 3 8
TNM stage
  I 24 67
  II 6 17
  III 5 14
  IV 1 3
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Real-time qPCR. Twenty-three genes were selected for evalua-
tion in the present study. These genes should be in the aberrant 
loci by array CGH and involved in biological processes with 
potential enhancing effects on tumor development and 
progression, such as cell proliferation, cell cycle control, cell 
death, cell adhesion and transcriptional regulation. Twenty 
genes were selected from regions of genomic gain and 3 genes 
were from frequently deleted regions.
Real-time qPCR analysis was performed using the ABI 
PRISM 7700 Sequence Detection system (PE Applied 
Biosystems). Primer and probe sets of the selected genes 
were commercially obtained (Assay-on demand TaqMan® 
Gene Expression Assays; Applied Biosystems). Samples were 
analyzed in duplicate and repeated for verification where 
appropriate. The comparative Ct method was used for the 
calculation of relative level of a test gene in a given tumor 
sample normalized according to β2M as reference for cDNA 
input. Results were presented as log2-transformed ratios 
between the tumor and pooled normal lung samples.
Statistical analysis. Statistical analysis was performed 
with the SPSS 18.0.0 software. Chi-square or Fisher's exact 
test was used to compare aberrant loci between tumors of 
different clinicopathological characteristics. Student's t-test 
for independent samples was used for the comparison of mean 
expression levels between different clinicopathological groups 
for individual genes. A two-sided P-value of <0.05 was taken 
as indicating a statistically significant result.
Results
Genomic CNA identified by array CGH. All the 36 ADs 
analyzed showed genomic imbalances, with a mean of 
221.6±168.4 (8.5±6.4%) aberrations per tumor. Overall, DNA 
gains (mean, 131.6) were more frequent than losses (mean, 
90.1). Graphical representation of the alteration frequencies of 
all loci along each chromosome is presented in Fig. 1.
The distribution of DNA imbalances was non-uniform. 
Clustering of aberrations was observed, where multiple 
altered loci were found in contiguous genomic sites or 
closely within the same cytogenetic band. These clustered 
alterations were mainly found within 1p, 1q, 5p, 5q, 7p, 7q, 
8q, 11q, 12p, 13q, 16p, 17q and 20q for DNA gain and within 
6q, 9p, 10q and 18q for DNA loss. Regions containing altera-
tions in 6 or more tumors are listed in Table Ⅱ. The genomic 
distances they spanned ranged from 0.3 to 8.4 Mb. The most 
frequently gained loci were within 5p15.33-p15.31 (44.4%), 
20q13.31-20q13.33 (38.9%), 8q24.21-q24.3 (36.1%), 16p13.3-
p13.12 (36.1%), followed by 1p36.32, 1q32.1 and 17q25.3 
(33.3%). The commonest loci of loss were within 9p23 (36.1%), 
followed by 6q16.3 (30.6%).
Another pattern of CNA consisted of focal aberrations 
spanned by single clones which were found in almost all chro-
mosomes. The most frequently altered loci were DNA gain 
involving 6p22 at 15.6 Mb (clone RP1-147M19, 30.6%), 7p13 
at 47.1 Mb (clone AC073341.10, 27.8%) and 22q12 at 31.5 Mb 
(clone Z73979.1, 27.8%); and DNA loss involving 1p21 at 
103.9 Mb (clone RP11-259N12, 30.6%), 6q12 at 67.1 Mb (clone 
RP11-80L16, 41.7%), 8q21 at 86.8 Mb (RP11-96G1, 30.6%) 
and 14q12 at 28.6 Mb (clone RP11-125A5, 38.9%).
High-level copy gains were identified in 16 of the 36 tumors. 
Nine loci showed recurrent gains involving at least 2 cases. 
They were focused at 2 regions, comprising 7p21.1-p15.3 (18.1 
to 21.2 Mb) spanned by 3 clones (RP11-70K3, RP11-51L23 and 
CTB-23M10) and 20q13.31-q13.33 (56.6 to 62.4 Mb) spanned 
by 6 clones (RP5-907D15, RP5-1043L13, RP5-1107C24, 
Figure 1. Copy number alteration profiles of primary lung AD by array CGH. Frequencies of DNA (A) gain and (B) loss are plotted against chromosomal 
positions indicated along the x-axis.
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Table Ⅱ. Clustered aberrations of DNA gain (upper panel) and loss (lower panel) spanned by multiple clones detected by array 
CGH in lung adenocarcinomas.
Cytoband Region size Clone name Chromosome start position (Mb) % Gain (n=36)
1p36.32 1.4 Mb RP1-163G9 chr1_3.0 33.3
    RP11-447M5 chr1_4.2 27.8
1p36.23-p36.21 3.3 Mb RP11-476D13 chr1_9.2 22.2
  AL031984.13 chr1_10.4 22.2
  RP5-888M10 chr1_12.4 16.7
1q21.2-q21.3 3.3 Mb RP4-790G17 chr1_147.0 22.2
  RP11-71L20 chr1_148.1 25.0
    RP1-148L21 chr1_150.3 22.2
1q25.3 1.5 Mb RP11-63O2 chr1_180.7 22.2
  RP11-79I7 chr1_182.0 19.4
1q32.1 3.9 Mb RP11-150L7 chr1_197.9 16.7
  RP11-246J15 chr1_198.9 16.7
  RP11-335O13 chr1_199.8 25.0
  RP11-80N9 chr1_201.4 16.7
    RP11-243M13 chr1_201.6 33.3
1q44 3.4 Mb RP1-241M7 chr1_240.7 19.4
  RP11-91C5 chr1_242.5 22.2
  RP11-656O22 chr1_244.1 22.2
5p15.33-p15.31 3.4 Mb RP11-20B3 chr5_3.1 44.4
  RP11-89N22 chr5_4.1 36.1
    AC010635.6 chr5_6.3 22.2
5p15.31-p15.2 5.0 Mb RP11-91M12 chr5_9.9 19.4
  RP11-145B1 chr5_10.3 25.0
  RP11-72C10 chr5_10.7 19.4
  RP11-79G1 chr5_11.1 19.4
  RP11-81P9 chr5_14.7 19.4
5q31.3 0.8 Mb RP11-79K4 chr5_140.3 25.0
  RP11-15J20 chr5_140.9 16.7
    RP11-55M16 chr5_141 19.4
7p21.1 3.5 Mb RP11-89B15 chr7_15.4 25.0
  RP11-123E5 chr7_17.3 19.4
  RP11-70K3 chr7_18.1 16.7
  RP11-384L2 chr7_18.7 19.4
7p15.1-p14.3 3.5 Mb RP11-242I4 chr7_30.2 25.0
  AC018648.5 chr7_32.6 22.2
    RP11-89N17 chr7_33.5 22.2
7q11.21-q11.22 2.5 Mb RP11-91C6 chr7_65.0 16.7
  RP11-89D15 chr7_67.4 25.0
8q24.21-q24.3 4.2 Mb RP11-13A18 chr8_141.6 36.1
  RP11-349C2 chr8_145.6 25.0
    CTC-261I1 chr8_145.7 33.3
11q13.3-q13.5 5.0 Mb AP001271.4 chr11_70.0 22.2
  RP11-168B13 chr11_74.8 22.2
  RP11-91P18 chr11_74.9 25.0
11q14.2 1.2 Mb RP11-80F20 chr11_86.5 19.4
    RP11-876F8 chr11_87.7 25.0
12p13.33-p13.31 5.3 Mb RP11-598F7 chr12_0.0 19.4
  RP11-543P15 chr12_3.1 25.0
  RP11-319E16 chr12_5.2 19.4
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RP5-1005F21, RP5-885L7 and RP1-81F12). No locus of high 
level loss was detected in the tumors studied.
CNA and clinicopathological correlations. Comparison 
between tumors with different clinicopathological features 
showed a trend of higher total and mean number of genetic 
aberrations in tumors showing larger size (≥2 cm), lymph node 
metastasis, higher pathological stages (stage II or higher), 
moderate/poor differentiation and previous or current tobacco 
exposure. The difference, however, was not statistically 
Table Ⅱ. Continued.
Cytoband Region size Clone name Chromosome start position (Mb) % Gain (n=36)
13q31.1-q31.2 0.7 Mb RP11-753M10 chr13_86.4 19.4
    RP11-29P20 chr13_87.0 22.2
13q34 3.2 Mb RP11-474D23 chr13_110.8 22.2
  RP11-245B11 chr13_113.8 19.4
16p13.3 5.9 Mb RP11-344L6 chr16_0.0 22.2
  CTB-191K2 chr16_0.1 30.6
  RP11-334D3 chr16_0.9 36.1
  RP11-417B20 chr16_1.4 25.0
  RP11-433P17 chr16_3.3 16.7
  RP11-89M4 chr16_4.5 16.7
    RP11-349I11 chr16_5.7 16.7
16p13.13-16p13.12 3.4 Mb RP11-396B14 chr16_11.1 19.4
  RP11-81F1 chr16_11.2 30.6
  RP11-165M1 chr16_12.3 19.4
  RP11-91M7 chr16_14.4 16.7
17q25.3 3.1 Mb RP11-165J13 chr17_74.7 33.3
  RP11-46E14 chr17_75.3 22.2
    CTB-50C4 chr17_77.8 16.7
20q13.31-20q13.33 8.4 Mb RP5-885A10 chr20_54.0 22.2
  RP4-749H19 chr20_54.9 36.1
  RP5-907D15 chr20_56.6 25.0
  RP5-1043L13 chr20_58.2 38.9
  RP5-1040G13 chr20_59.1 33.3
  RP5-1107C24 chr20_59.9 30.6
  RP5-1005F21 chr20_60.1 30.6
  RP5-885L7 chr20_60.9 25.0
  RP4-583P15 chr20_61.8 33.3
  AL118506.27 chr20_62.0 25.0
    AL137028.9 chr20_62.4 22.2
Cytoband Region size Clone name Chromosome start position (Mb) % Loss (n=36)
6q16.3 0.5 Mb RP11-90O11 chr6_101.9 30.6
  RP11-79O12 chr6_102.2 16.7
9p24.2 1.6 Mb RP11-79M14 chr9_2.6 22.2
  RP11-32F11 chr9_3.1 25.0
    RP11-31M2 chr9_4.1 16.7
9p24.1 1.1 Mb RP11-79K3 chr9_7.3 16.7
  RP11-376O21 chr9_8.2 25.0
9p23 3.1 Mb RP11-91E3 chr9_9.6 30.6
  RP11-32D4 chr9_11.5 36.1
    RP11-328C23 chr9_12.5 19.4
10q21.1 4.4 Mb RP11-75M12 chr10_52.8 27.8
  RP11-79A2 chr10_57.1 25.0
18q22.1-q22.2 0.3 Mb RP11-90A7 chr18_64.7 25.0
    RP11-49H23 chr18_64.9 22.2
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significant. Tumors of more aggressive phenotypes showed 
more frequent alterations in 13q for DNA loss, and 1q, 2q, 
3q, 5q and 17q for DNA gain. Furthermore, tobacco-exposed 
patients showed more often loss at 8q21.3, 9p24.1 and gain 
at 6p22.1, while non-smokers showed more frequent gains at 
1q44, 8q13.3, 22q12.3 and Xp22.12 (Table Ⅲ).
FISH analysis. Dual-color FISH analysis of a selective loci at 
20q13.3 which show high-level gain were performed in 5 of 8 
amplified cases of paraffin sections. The average ratio of test 
to reference signal was 2.31, which showed agreement with the 
results detected by array CGH (Fig. 2).
Real-time qPCR. For the 20 genes located in regions of DNA 
gain, the tumor to normal expression ratios investigated by 
real-time qPCR ranged from 0.22 to 4.89. While for the 3 genes 
located in regions of genomic loss, the tumor to normal expres-
sion ratios were -0.23, 1.14 and 2.91, respectively (Table Ⅳ). 
The concordance observed between the genomic and expres-
sion changes for most of the genes suggested that they could 
be candidate oncogenes that contributed to the development 
of lung AD, while none of the genes showed expression levels 
that were significantly associated with the cliniopathological 
parameters.
Discussion
The present study utilized an array platform that consists of 
large insert DNA template clones covering the genome at 
an average resolution of 1 Mb to characterize the profiles of 
genomic imbalances in primary lung AD. Recurrent aberra-
tions were found clustered in regional distribution spanned by 
multiple clones, and in focal distribution spanned by single 
clones. These loci correlated with results of our previous 
array CGH study performed on non-small cell lung cancer 
(NSCLC) cell lines, and corresponded to well-known aberra-
tions of lung cancers defined by other array CGH studies (8,9). 
The common patterns of genomic changes indicate that lung 
cancer-related genes are likely to be contained within these hot 
spots of alterations.
5p15.33 is the most frequently gained locus in the present 
study. A pooled analysis from East Asia totaling 1164 lung 
ADs revealed that genetic variation in the CLPTM1L-
TERT locus of 5p15.33 was directly associated with the 
risk of lung cancer, most notably AD (10). Other studies 
also found 5p15.33 locus influence lung cancer risk (11,12). 
The second frequently gained region involves an 8.4-Mb 
segment of gain at 20q13.31-q13.33 (56.5 to 62.1 Mb). This 
region is noteworthy as it is one of the commonest aberra-
tions in lung cancer as well as tumors of the gastric cancer 
and pancreatic cancer (13-15). The FISH analysis on tumor 
samples confirmed modest DNA gains. The third altered 
locus of 8q24.21-q24.3 is a known site of DNA gains and 
amplifications and contains the c-Myc oncogene. Different 
array CGH studies have found aberrant loci correlating to 
this region (16,17). The detection of these multiple loci by 
independent studies suggests the presence of multiple onco-
genes at these regions.
Comparison of tumors of different clinicopathological 
groups was performed to identify genomic markers of poten-
tial diagnostic and prognostic importance. All the aberrant 
loci that showed statistical significance were more common 
in tumors of more aggressive phenotypes, i.e., poor differen-
tiation, lymph node metastasis and higher disease stage. This 
Figure 2. Dual-color FISH analysis. Increased test (RP5-885L7, 20q13.3, 
labeled in orange) to control (CEP-20, labeled in green) signal ratios in tumor 
sample.
Table Ⅳ. Candidate gene expression levels by real-time qPCR 
in 36 cases of lung adenocarcinomas.
Gene  Array  Expression Validation
symbol Cytoband CGH level (log2) (DNA/RNA)
CMM 1p36.32 Gain 0.48 Yes
PAX7 1p36.2 Gain 3.44 Yes
ILF2 1q21.3 Gain 3.02 Yes
MUC1 1q22 Gain 2.20 Yes
ELF3 1q32.1 Gain 1.96 Yes
CHI3L1 1q32.1 Gain 2.23 Yes
SMYD3 1q44 Gain 2.99 Yes
TERT 5p13.33 Gain 4.89 Yes
PRDM13 6q16.3 Loss 1.14 No
AGR2 7p21.1 Gain 4.34 Yes
SBDS 7q11.21 Gain 2.35 Yes
RECQL4 8q24.3 Gain 3.31 Yes
OVC 9p24.2 Loss 2.91 No
DKK1 10q21.1 Loss -0.23 Yes
CCND1 11q13.3 Gain 3.02 Yes
ETV6 12p13.33 Gain 1.39 Yes
GAS6 13q34 Gain 0.22 Yes
AXIN 16p13.3 Gain 1.79 Yes
EMP2 16p13.13 Gain 3.56 Yes
ASPL 17q25.3 Gain 2.02 Yes
STK6 20q13.31 Gain 2.97 Yes
TFAP2C 20q13.31 Gain 1.32 Yes
EEF1A2 20q13.33 Gain 4.52 Yes
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observation corroborates the concept that tumor progression is 
enhanced by genomic instability and accumulation of genetic 
abnormalities.
Several studies have evaluated DNA alterations in tumors 
of different tobacco exposure using different approaches. 
However, the chromosomal regions characterizing tobacco- 
or non tobacco-induced lung AD remain unclear. By cluster 
analysis of genomic aberrations in 55 AD detected by a 
cancer gene-rich array, Shibata et al (18) identified subgroups 
associated with female non-smokers, male current or previous 
smokers and a group with mixed gender and tobacco history. 
Loci of DNA gains on 1p, 4p, 11p, 12q, 16p, 17q, 19q, 20p, 
20q and 22q, and losses on 1p, 6q, 10q, 13q, 15q and 18p were 
associated with non-smokers, while loci of 19q gain and 22q 
loss were associated with smokers. Our results cannot be 
directly compared since our array did not specifically span 
tumor genes. Nevertheless, 22q12.3 (31.5 Mb) which shows 
DNA gain in 10 of 22 non-smokers compared to 0 of 14 
tobacco-exposed tumors (P=0.003) is located close to one of 
their reported loci (22q12.2 gain) in non-smokers. Analysis 
of a larger number of tumors and the use of identical, high-
resolution array platforms in different populations would be 
necessary for definitive identification of genomic markers 
associated with different tobacco exposure and clinicopatho-
logical profiles.
It is a common assumption that chromosomal gains and 
losses have ‘dosage effects’ on the expression of at least some 
of the genes within these regions, which should be good candi-
dates for involvement in carcinogenesis. The concordance 
observed between the genomic changes and expression level 
by real-time qPCR for the most selected genes in the present 
study suggested that they could be candidate oncogenes or 
tumor suppressor genes that contributed to the development 
of lung AD. Some of them had been investigated in clinical or 
in vitro studies and results supported their putative oncogenic 
roles. For example, PAX7 gene on 1pter-p33 that encodes a 
transcription factor was most amplified in lung squamous cell 
carcinoma (19), and elevated expression of MUC1 on 1q22 
contributed to smoking-induced lung cancers that were driven 
by inflammatory signals of macrophages (20). One of Stat3 
downstream gene products, chitinase 3-like 1 (CHI3L1, in 
region 1q32.1) protein, was found to be a potential biomarker 
of inflammation-induced lung cancer by a study of lung tumor 
mouse models (21). TERT was locused on 5p15.33 which was 
one of the susceptibility loci from a genome-wide association 
study of lung cancer in never-smoking Asian women (8), and 
was the highest expressed gene in the present study. Several 
studies using animal models and human NSCLC tissues have 
reported that TERT mRNA and protein were overexpressed 
in lung tumors compared with normal lung tissues (22,23). 
The 7p genes AGR2 was revealed to be significantly overex-
pressed in lung AD by comparison with SCCs or normal lung 
tissue (24). Among the 3 genes located in the loss region, only 
Dickkopf1 (DKK1, in region 10q21.1) was underexpressed 
compared to normal lung tissue. DKK1 is the predominant 
secretory antagonist of the Wnt/β-catenin signal, suggesting 
that if DKK1 were not precisely regulated, it could result in 
tumor formation and progression. In fact, several clinical 
studies demonstrated that DKK1 was downregulated in 
melanoma and breast cancer (25,26). The observation that 
CCND1 (in region 11q13.3) was amplified and overexpressed 
in a fraction of NSCLC when compared with normal lung was 
strong evidence implicating the inappropriate expression of 
CCND1 in lung carcinogenesis (27). Amongst genes located 
in the recurrently gained 20q13.3 region, TFAP2C not only 
were highly expressed in breast cancer, but also associated 
with reduced survival (28). And EEF1A2 were amplified or 
overexpressed in various cancers including NSCLC which 
highlights its oncogenic potential (29).
None of the genes showed expression levels that were 
significantly associated with the clinicopathological parame-
ters, indicating that the currently studied genes were not likely 
candidates that mediated the differences in tumor differentia-
tion and behavior implicated by the array CGH analysis. The 
possible explanations for failing to demonstrate these relations 
could be that gene-mining based on the strategy of genomic, 
expressional and functional correlations was insufficient in 
the clinical context, reflecting the complexity of genetic and 
transcriptional interactions in tumor development. Moreover, 
since lung ADs are known to consist of heterogeneous tumor 
populations, it might be worthwhile to conduct the investiga-
tion in a larger sample of well controlled, homogeneous tumor 
population when a candidate tumor gene with strong evidence 
is considered.
In conclusion, we used array CGH to identify loci of 
frequent DNA aberrations in primary lung AD. Real-time 
qPCR confirmed cancer-related genes in regions with CNA 
from array CGH data. The limitations of the present study are 
the small number of samples and further studies are needed to 
validate our results. The identified aberrations and candidate 
genes can be used as starting points for more specific inves-
tigations for pathogenesis in primary lung AD, as well as in 
tumors of different etiological or phenotypic characteristics.
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